Company Description
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Country | Canada |
| Founded | 1996 |
| IPO Date | Nov 5, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 259 |
| CEO | Ian Mortimer |
Contact Details
Address: 3650 Gilmore Way, Suite 200 Burnaby, BC V5G 4W8 Canada | |
| Phone | 604 484 3300 |
| Website | xenon-pharma.com |
Stock Details
| Ticker Symbol | XENE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001582313 |
| CUSIP Number | 98420N105 |
| ISIN Number | CA98420N1050 |
| Employer ID | 98-0661854 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian C. Mortimer C.M.A., CPA, M.B.A. | President, Chief Executive Officer and Director |
| Sherry Aulin C.A., CPA | Chief Financial Officer |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy and Innovation |
| Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Andrea DiFabio J.D. | Chief Legal Officer and Corporate Secretary |
| Shelley McCloskey B.A. | Executive Vice President of Human Resources |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
| Sheila M. Grant M.B.A., M.Sc., MBA | Executive Vice President of Research & Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 9, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 12, 2024 | 144 | Filing |
| Jun 12, 2024 | 144 | Filing |
| Jun 5, 2024 | 144 | Filing |
| Jun 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |